Format

Send to

Choose Destination
See comment in PubMed Commons below
J Cardiovasc Med (Hagerstown). 2007 Oct;8(10):799-802.

Patient risk profile and benefit from an invasive approach in the initial management of non-ST-segment elevation acute coronary syndrome.

Author information

  • 1Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy. giuseppe.tarantini.1@unipd.it

Abstract

BACKGROUND:

Routine use of an invasive strategy (IS) has been shown to exceed a conservative strategy in reducing myocardial infarction (MI), angina and re-hospitalization rate in patients with non-ST elevation acute coronary syndrome (NSTEACS). The present study aimed to analyse, by use of randomized trials data, whether the risk profile of patients with NSTEACS influences the survival benefit of the IS over a conservative strategy from randomization to end of follow-up (range 6-24 months).

METHODS:

Eight studies were identified from 1970 to 2005. A fixed effect-meta-regression analysis for: (i) the log-odds ratio on death and (ii) the log-odds ratio on death/MI against the odds of death/MI in the control group was made.

RESULTS:

IS was associated with a significant reduction in death/MI [12% versus 13.7%, odds ratio (OR) = 0.86, P = 0.009], but not in mortality (5.1% versus 5.5%, OR = 0.92, P = 0.34). There was evidence of heterogeneity in the outcome mortality (P = 0.06 for heterogeneity) and the composite of death/MI (P = 0.01 for heterogeneity). Sensitivity analysis demonstrated that the source of heterogeneity was significantly related to the outlier VANQWISH trial. When the latter was removed from the analysis, IS was related to a significant reduction of both death (3.9% versus 4.9%, OR = 0.81, P = 0.04, P heterogeneity = 0.35) and death/MI (10% versus 12.1%, OR = 0.81, P = 0.001, P heterogeneity = 0.07).

CONCLUSIONS:

The main finding of this meta-analysis is that, compared to a conservative strategy, the benefits of IS for the management of NSTEACS in terms of death/MI reduction are related to the patient's risk profile.

PMID:
17885517
DOI:
10.2459/JCM.0b013e3280110605
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center